TherapeuticsMD (TXMD) Misses Q4 EPS by 5c

TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.15), $0.05 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $22.6 million versus the consensus estimate of $21.89 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
• CEMEX, S.A.B. de C.V. (CX) Tops Q1 EPS by 5c
• United Bankshares (UBSI) Misses Q1 EPS by 1c